Biogen to pay $1.25 billion for patents to MS drugs; Supreme Court to hear Novartis case over Zarxio delay; Merck KGaA inks big-data deal
Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise
Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.
Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients
Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences
Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle
Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug
As the effectiveness of in-person detailing wanes, how will cloud-based content solutions adapt?
To break through and drive a high level of physician interaction, Havas Life Metro and Genentech created an interactive self-guided digital storytelling experience to explain the unique mechanism of action of Gazyva.
Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines
Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus
Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight
Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.
Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated
Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.
Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin
Purdue Pharma reportedly knew about OxyContin trafficking; Amgen's Repatha approved for monthly dosing option; Clinton proposes new healthcare measures
Hillary Clinton receives more donations from pharma than republicans; biotech reps have highest salaries; NICE recommends Yervoy-Opdivo combo
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
Antidepressants are often used to treat conditions other than depression; the FDA delays decision on Duchenne drug; Lilly and Pfizer develop new painkiller
Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug
AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.
Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.
Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations
Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.
Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review
After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.
Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza
- Day 1 at JP Morgan: Pricing is top of mind for pharma CEOs
- When it comes to PCSK9s, payers resisted — and sales flopped
- Five things for pharma marketers to know: Thursday, January 12, 2017
- Infographic: Can pharma give doctors what they want?
- Day 2 at JP Morgan: Change is coming, but which drugmakers will stay on top?
- Five things for pharma marketers to know: Tuesday, January 17, 2017
- Trump administration raises questions for rare-disease drugmakers
- If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold
- Five things for pharma marketers to know: Friday, January 13, 2017
- Klick Health's Elliot Langerman on the Power of Persuasion